Business
European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114
European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"\nEuropean Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114 \n\nEuropean Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114\n\n\n MISSION VIEJO, CA --(Marketwired - April 18, 2016) - Aeolus Pharmaceuticals (OTCQB: AOLS)\n \n AEOL 11114 Is Subject of Michael J Fox Foundation Research Grant Program\n \n \n Efficacy Demonstrated in Two Parkinson's Disease Models \n \n \n IND Filing for Parkinson's Disease Targeted for First Half of 2017\n \n \n Aeolus Pharmaceuticals, Inc.\n (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that the European Patent Office issued patent number 2625180 covering the composition of matter for its oral Parkinson's disease drug AEOL 11114. The Company also announced that a patent for AEOL 11114 has been allowed in Japan. AEOL 11114 has demonstrated neuro-protective activity in models of Parkinson's disease and other indications. The compounds were invented by Brian J. Day, PhD at National Jewish Health and Manisha Patel, PhD at the University of Colorado, Anschutz Medical Campus, Department of Pharmaceutical Sciences in collaboration with Aeolus Pharmaceuticals and under two research grants from the Michael J. Fox Foundation for Parkinson's disease. Aeolus has obtained worldwide, exclusive licenses to develop the compounds from National Jewish Health and the University of Colorado. Aeolus is currently working on optimization of the AEOL 11114 manufacturing process and formulation. Upon completion of this work, IND-enabling safety and toxicology studies are planned to begin in the third quarter of 2016. Aeolus plans to file an IND for the treatment of patients with Parkinson's disease during the first half of 2017. The Company intends to pursue a partner with clinical development expertise in this indication to initiate clinical studies.Preclinical studies funded by the Michael J. Fox Foundation in two models of Parkinson's disease demonstrated that AEOL 11114 reduced oxidative stress and damage, mitigated dopamine depletion, prevented loss of nigrostriatal dopaminergic neurons, the most important neuropathological feature of Parkinson's disease, and improved Parkinson's disease-like ...